BridgeBio Pharma (BBIO) Common Equity (2018 - 2026)

BridgeBio Pharma has reported Common Equity for 9 years, with the latest figure at -$2.3 billion in Q1 2026.

• Quarterly Common Equity fell 39.06% year-over-year to -$2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 39.06% YoY) and the FY2025 annual result came in at -$2.1 billion, down 42.41% from the prior year.
• Common Equity retreated to -$2.3 billion in Q1 2026 per BBIO's latest filing, from -$2.1 billion in the prior quarter.
• Over five years, Common Equity peaked at -$1.0 billion in Q2 2022 and troughed at -$2.3 billion in Q1 2026.
• A 5-year average of -$1.4 billion and a median of -$1.2 billion in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity tumbled 167.36% in 2022, then climbed 19.86% in 2024.
• Over 5 years, Common Equity stood at -$1.2 billion in 2022, then retreated by 8.02% to -$1.3 billion in 2023, then decreased by 8.54% to -$1.5 billion in 2024, then tumbled by 42.41% to -$2.1 billion in 2025, then fell by 9.75% to -$2.3 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$2.3 billion, -$2.1 billion, and -$1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.